Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌(NPC)。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌(UC)。⑷用于食管鳞癌一线治疗。
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Xiaomin Ou, Shanghai, China
Linear Clinical Research, Nedlands, Western Australia, Australia
Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Zhiguo Luo, Shanghai, Shanghai, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Renji Hospital, Shanghai, Shanghai, China
Sun Yat-sen University Cancer Center, Guang Zhou, China
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.